AI summary by TwinMind
Lec 26: Health Care Economics
MIT OpenCourseWare
44m 48s
Healthcare Spending Growth and Value Assessment
- US healthcare spending: 4% GDP (1950) → 18% GDP (today)
- Healthcare now largest single sector of US economy
- Overall spending increase has been worth it despite high costs
- Premature babies: 4x more likely to die in 1950, now survive at 4 pounds
- Heart attack survival: 4x higher today vs 1950
- Orthopedic surgery: week-long hospital stays → outpatient arthroscopic procedures
- Economic proof of value: no demand for 1950s healthcare at 1950s prices
- US spends ~33% more than expected based on income level compared to other countries
Distributional Consequences and International Comparisons
- US ranks 16th globally in infant mortality despite high spending
- Poor outcomes driven by bottom of society, not accessible population
- White babies in America: same survival rates as Europe
- Black babies in America: lower survival than black babies in Barbados
- 17-year life expectancy gap between neighborhoods (Freddie Gray example)
- Annual medical tourism: 1 million people come to US for care, none leave for treatment elsewhere
- System delivers excellent outcomes for those with access but highly inequitable
Pre-ACA Insurance Landscape (2009)
- 60% employer-sponsored insurance
- 20% public insurance (Medicare for elderly, Medicaid for poor)
- 20% uninsured or individual market purchasers
- Individual insurance market broken due to adverse selection
- Insurers denied coverage for pre-existing conditions
- Dropped coverage when people became sick
- ~50 million Americans uninsured (15% of population)
Three-Legged Stool Solution
Leg 1: Community Rating (Non-discrimination)
- Insurers cannot charge different prices based on health status
- Can vary by age and geographic area within reason
- Cannot charge women more than men
- Previous state attempts (1990s) failed when implemented alone - markets collapsed
Leg 2: Individual Mandate
- Required to enforce pooling equilibrium
- Individuals must buy insurance or pay fine
- Prevents adverse selection death spiral
Leg 3: Subsidies
- 2004: Average family plan $12,000, poverty line $18,000 for family of four
- Commonwealth Care: subsidies for those below 3x poverty line
- Sliding income scale for premium payments
Massachusetts Implementation Success
- Passed 2005/2006, enormous policy success
- Maintained 60%+ public support throughout
- Uninsurance rate fell by 2/3 to 3% (comparable to European levels)
- Fixed broken non-group market: new insurers entered, prices fell 50%
- Bipartisan support initially - Republican governor, conservative think tank speakers
Affordable Care Act (ACA)
- Essentially Massachusetts law scaled nationally
- Same three-legged stool approach:
- Community rating
- Individual mandate
- Subsidies through Medicaid expansion (up to 133% poverty line) and marketplace subsidies (133-400% poverty line)
- Covered ~20 million Americans by 2016
- Policy success but political failure initially
Political Economy Lessons
- Status quo bias: easier to preserve existing programs than create new ones
- 4-year implementation delay allowed opposition messaging without visible benefits
- By 2017 support exceeded 50% for first time
- Medicare example: "keep government hands off my Medicare" despite being government program
- Behavioral economics applications to political decision-making
Healthcare Cost Crisis and Market Failures
- ~33% of US healthcare spending doesn't improve health outcomes
- Healthcare market exhibits every type of market failure:
Market Power/Monopoly
- No shopping ability during emergencies (ambulance example)
- Geographic monopolies (Nantucket hospital)
- Reputational monopolies (David Ortiz choosing MGH over Beth Israel)
Information Asymmetries
- Patients cannot assess necessity of tests/treatments
- Doctor-patient information imbalances
Externalities
- Uninsured spreading disease
- EMTALA law requiring emergency treatment
- Cost-shifting from uninsured to insured patients
Price Regulation Differences
- US only developed country not regulating healthcare prices
- 50% government/50% private spending mix (similar to other countries)
- Key difference: other countries regulate private sector prices
- Examples of price differences:
- MRI: $1,500 (Boston) vs $75 (Japan)
- Typical drugs/procedures: US pays 2-3x European prices
Medicare Drug Reimbursement Example
- Injectable drugs reimbursed at cost + 6.5% of drug price for physician effort
- $100 drug = $7.50 physician payment
- $1,000 drug = $75 physician payment (same effort)
- 20 senators initially supported reform, 80 opposed it after oncologist lobbying
Innovation vs Price Regulation Debate
- Counterarguments to price regulation:
- Government implementation failures (valid concern)
- Innovation reduction (less valid)
- US leads in pharmaceutical R&D, funded by high drug prices
- Basic science R&D primarily government-funded (NIH)
- MIT study: NIH grants show higher innovation returns than private R&D
- Regulation could fund more basic science through savings
Future Projections and Challenges
- Current 18% GDP spending projected to reach 40% by end of century
- Unsustainable trajectory requiring intervention
- Recent progress: Inflation Reduction Act regulated prices for 10 drugs
- Status quo bias makes reform difficult (healthcare costs = healthcare income)
- Two critical policy challenges for next generation: healthcare costs and climate change
